ZYLOXTB

2190
18.1700.60% ( -0.110 )
Delay Closed: Nov 16, 16:08:11

Overview

ZYLOXTB (2190)

Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices in the People’s R...

Open
18.190
High
18.190
Low
17.800
Prev. Close
18.280
Volume
502.02K
Turnover
9.03M
Avg Price
17.997
Bid/Ask Ratio
-64.71%
Amplitude
2.13%
52wk High
27.748
Volume Ratio
2.03
Turnover Ratio
0.16%
52wk Low
17.100
HK Mkt Cap
5.85B
Market CapHKD
5.99B
P/ETTM
17.07
P/EDynamic
14.32
P/EStatic
--
EPSTTM
1.06
EPSDynamic
1.27
EPSStatic
--
BVPS
10.39
P/B
1.75
HK Shares
322.06M
Dividend YieldTTM
1.40%
DividendTTM
0.255
Shares
329.84M
Min lot size
500
Currency
HKD

ZYLOXTB Analyst Rating

View more

Forecast & Rating

Nov 9, 2026
Price forecast
HK$31.0871.07%
Forecast & RatingStrong buy
5analysts
  • Strong buy60.00%
  • Buy40.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 13

    Zylox-Tonbridge closed up about 3.5% at HK$18.97 against the prior close of HK$18.33, driven by its joint HK$1.48 billion move with GL Capital to buy a 16.7% LifeTech stake, of which the company funds HK$889 million while pursuing a potential merger and a concurrent H-share placement. The session traced a dip-and-recover shape: it opened at HK$18.85, slid to HK$17.70 by 13:27 BJ time, then climbed back through the afternoon to settle at HK$18.97. Fundamentals underpin the move, with Q2 2026 revenue of HK$365.0 million up 38.2% YoY, net profit of HK$104.9 million up 58.0%, operating income up 134.4%, a 28.75% net margin and EPS of HK$0.3292 up 62.4%. Still, the shares sit below the MA20 of HK$19.27 and MA60 of HK$20.48, down 16.8% year-to-date and 32.3% below the 52-week high of HK$28, at 17.8x PE and HK$6.26 billion market cap, while placement dilution and integration risk remain open.

  2. Nov, 12

    Zylox-Tonbridge fell 2.47% to HK$18.20 in a spike-and-fade session, as profit-taking followed a 12% one-day jump on the proposed HK$1.48 billion purchase of a 16.7% stake in LifeTech Scientific alongside an H-share placement; the stock opened at HK$19.11 and slid to an intraday low of HK$18.14 at 13:21 BJ before closing near the day's low. Fundamentals still underpin the story, with Q2 2026 revenue up 38.23% year on year to HK$365.0 million, net profit up 58.04% to HK$104.9 million, operating income up 134.4% and first-half net profit up 47.8% to RMB179.1 million on a 28.75% net margin. Yet the shares trade below the MA20 of HK$19.38 and MA60 of HK$20.50, down 20.18% year to date, 35% below the 52-week high of HK$28 and only 6.43% above the 52-week low of HK$17.1, at 17.1x PE with turnover of just HK$12.98 million and a 0.22% turnover rate, while placement dilution concerns keep rebounds in check.

  3. Nov, 9

    Shares opened up 8.3% at HK$21.00 but unwound through the session to close at the intraday low of HK$18.96, down 2.2%, as the plan to buy a 16.7% stake in LifeTech Scientific alongside GL Capital for HK$1.48 billion, paired with a concurrent H-share placement at roughly a 13.5% premium raising about HK$864 million net, put dilution and cash-out concerns ahead of platform consolidation; the same deal had lifted the stock more than 12% in the prior session. Fundamentals remain firm: Q2 2026 revenue of HK$365.0 million rose 38.2% year on year, net profit HK$104.9 million gained 58.0%, EPS HK$0.3292 climbed 62.4% and operating income rose 134.4%, at a PE of 17.8x and PB of 1.83x. The close sits below the MA20 of HK$19.71 and MA60 of HK$20.56, down 16.8% year to date, 32.3% below the 52-week high of HK$28.00 yet 10.9% above the HK$17.10 low. Though repeated buybacks of about 53,000 shares for roughly HK$1.13-1.16 million per day since late September may cushion the downside near lows.

  4. Oct, 22

    ZYLOXTB opened at HK$21.02 and slid in a one-way decline, touching and closing at HK$19.40 in the afternoon session, roughly 5.4% below the prior close of HK$20.50, on thin turnover of 274,936 shares worth HK$5.47 million. The move contrasts with Q2 2026 results: revenue of HK$365.0 million, up 38.23% year on year, net profit of HK$104.9 million, up 58.04%, operating income up 134.4%, and EPS of HK$0.3292, up 62.39%. The price sits below both the MA20 of HK$20.958 and the MA60 of HK$20.554, down 13.2% year to date and 29.32% below the 52-week high of HK$28.00. Since mid-September the company has bought back about 53,000 to 55,500 shares almost daily, spending roughly HK$1.13 to 1.16 million each time, while AIH Capital added 118,000 shares near HK$20.50; though the light volume suggests such repurchases gave limited near-term price support.

  5. Oct, 13

    Supported by continued buybacks and interim results, the stock staged a low-open, dip-and-recover session, closing at HK$21.06 versus a prior close of HK$20.34, up about 3.5%, after an intraday low of HK$20.12 shortly after the open and a high of HK$21.14 at 13:31 BJ, on turnover of roughly HK$22.3 million. The company has repeatedly repurchased and cancelled shares in the HK$20.82-21.38 and HK$21.78-22.2 ranges, and most brokers rate it buy. Fundamentals echo the move: Q2 2026 EPS of HK$0.3292 rose 62.4% yoy, revenue of HK$365 million gained 38.2%, operating income climbed 134.4%, and first-half net profit rose 47.8% to RMB179.1 million, with GF Securities keeping a Buy rating. The price remains about 24.8% below its 52-week high of HK$28 and down 7.6% year-to-date, though it now stands above its MA20 of HK$21.05 and MA60 of HK$20.45. At 19.8x PE, however, further re-rating still hinges on earnings delivery.

News